Intellia Therapeutics: Leading the Way in Revolutionary Genome … – Best Stocks

Intellia Therapeutics: Revolutionary Genome Editing Techniques

Intellia Therapeutics (NASDAQ:NTLA), the clinical stage genome editing company, is all set to release its quarterly earnings data before the market opens on Thursday, May 4th. This Boston-based biotech firm engages in developing curative therapeutics that fix disease-associated genes with a single treatment.

What sets Intellia apart from others in the field is their revolutionary CRISPR/Cas9 system. Using a highly advanced gene editing technology, Intellia creates engineered cells, which help treat oncological and immunological diseases. The capability of CRISPR/Cas to permanently edit or correct disease-associated genes apply to patients for their lifetime, requiring no repeated dosing.

BMO Capital Markets upgraded Intellia from a market perform rating to an outperform rating and raised their price target for the company from $54.00 to $57.00 in March of 2017. Notably, William Blair restated an outperform rating on shares of Intellia in late March. As per reports, Wells Fargo & Company lowered Intellias price target from $135.00 to $120.00 and set an overweight rating on the stock in early January of this year.

Citigroup also provided support by upgrading Intellia from a sell rating to a neutral rating while dropping its price target for the firm from $48.00 to $39.00 in late January 2017. Finally, Oppenheimer decreased its price target on NTLA from $115.00 to $93.00 but gave it an outperform rating in late February based on current economic growth indicators.

All told, one equities research analyst gave the stock a sell-rating while three have issued hold ratings throughout 2016-17 period when these analyses were conducted by various firms. Overall, sixteen analysts rated the stock as buy. Data from Bloomberg reveals its consensus target price is $85.67 and the consensus rating is Moderate Buy.

Intellias gene-editing techniques have several utilities in healthcare, including basic research in genetics, cell-line engineering for producing beneficial proteins, development of advanced gene therapies and improving agriculture for food production.

We look forward to Intellias earnings data later this week to inform us further as to how very clear evidence suggests a burgeoning realm of opportunities.

Intellia Therapeutics Inc.s latest earnings report released on February 23rd, 2021, showed a quarter full of ups and downs for the biotechnology company. The report revealed that Intellia posted ($1.40) per share earnings for Q4, meeting the consensus estimate of ($1.40), while accumulating an impressive revenue of $13.60 million compared to analysts expectations of $10.71 million.

Despite Q4s net profit taking a hit as evidenced by the negative return on equity of 48.70%, Intellia realized an increase in revenue by 5.4% from the same quarter in the previous year. This is remarkable given that the previous years net earnings per share were ($1.09).

Analysts have projected that IntelliTherapeutics is set to buck up its operations with losses predicted to stand at $6 EPS both for this fiscal year and the next one to follow yet to come.

For investors interested in dabbling in this firm, at-$36.29 trading price within NASDAQ exchange rates located today, hovering between lowest and highest markers of $32.44 and $76.45 respectively within its 52-week game plan a market capitalization valuation of $3.20 billion is priced into NTLA stock.

Investment experts at Atria Wealth Solutions Inc., Canada Pension Plan Investment Board, Dynamic Technology Lab Private Ltd, Glenmede Trust Co-NA and First Republic Investment Management Inc have added new stakes totaling about $1,404 million some few years ago.

Nonetheless, Intellia Therapeutics has left investors starved since unrelenting market forces have weighed aggressively on their shares over time may probably need strategic repackaging efforts to fix their brands appeal amongst institutional clients? Time will tell if these sneaky tweaks will lead NTLA on a better path towards profitability soon enough!

Read this article:
Intellia Therapeutics: Leading the Way in Revolutionary Genome ... - Best Stocks